Elephas Biosciences Collaborates with Mount Sinai to Enhance Bladder Cancer Research Using elive™ Technology
In a groundbreaking partnership, Elephas Biosciences Corporation has announced the integration of its cutting-edge elive™ technology into Mount Sinai's Genitourinary Oncology Program. This innovative precision cutting technology will play a significant role in enhancing the research landscape for bladder cancer, more specifically in understanding how immunotherapy impacts patient outcomes.
The elive Edge is an automated cutting instrument designed to produce uniform live tumor fragments from tissue samples. These samples, which include those obtained from core needle biopsies and cored resections, will be utilized in ex vivo research targeting immunotherapy responses in bladder cancer patients. The aim is to unlock a deeper understanding of how different patient responses occur, ultimately leading to improved treatment strategies.
Bladder cancer has a high treatability rate when identified early. However, as the disease progresses, the treatment becomes increasingly complex. The advent of immunotherapy has provided new avenues for treatment; however, the variability in individual patient responses presents a challenge. Elephas aims to leverage its technology to identify and analyze these differences effectively.
Dr. Jonathan Anker, a leading Genitourinary Oncologist at Mount Sinai, expressed enthusiasm for using live tumor tissues, stating, "Working with live tumor tissue gives us an opportunity to gain additional insight into immunotherapy responses in bladder cancer. The ability to evaluate tissue from both core needle biopsies and cored resection samples will support our ongoing research."
Utilizing live tumor fragments represents a significant advancement in cancer research. As noted by Dr. Premal Patel, Chief Medical Officer at Elephas, there is mounting recognition of the value this approach brings to understanding drug responses in patients. The elive Edge technology will facilitate meticulous preparation and handling of these tumor samples, ensuring that they are suitable for research purposes.
Cancer remains a leading cause of mortality globally, and projections indicate that the number of patients could triple by 2060 if current trends continue. Despite the increasing number of immunotherapy options, only a small fraction of patients derive benefits from these treatments. Many eligible patients remain unidentified due to the unavailability of accurate predictive biomarkers.
Elephas addresses this pressing issue with its ex vivo platform, which evaluates how live tumor tissue reacts to various therapies, preserving the vital tumor microenvironment. By doing so, the elive platform aims to provide crucial insights into patient care and treatment choices for those battling cancer.
The collaboration between Elephas Biosciences and Mount Sinai represents an important step forward in bladder cancer research. By harnessing innovative technology to analyze live tumor tissues, researchers hope to uncover critical differences in how patients respond to therapies and guide future treatments.
To explore the implications of this collaboration further and learn more about the elive technology's potential, you can visit Elephas's official website at www.elephas.com or follow their journey on LinkedIn. As hospitals and research institutions continue to partner with technology developers, the fight against cancer gets a significant boost toward personalized medicine, driven by understanding the intricacies of individual responses to treatment.
Understanding the Technology
The elive Edge is an automated cutting instrument designed to produce uniform live tumor fragments from tissue samples. These samples, which include those obtained from core needle biopsies and cored resections, will be utilized in ex vivo research targeting immunotherapy responses in bladder cancer patients. The aim is to unlock a deeper understanding of how different patient responses occur, ultimately leading to improved treatment strategies.
The Importance of Early Diagnosis
Bladder cancer has a high treatability rate when identified early. However, as the disease progresses, the treatment becomes increasingly complex. The advent of immunotherapy has provided new avenues for treatment; however, the variability in individual patient responses presents a challenge. Elephas aims to leverage its technology to identify and analyze these differences effectively.
Dr. Jonathan Anker, a leading Genitourinary Oncologist at Mount Sinai, expressed enthusiasm for using live tumor tissues, stating, "Working with live tumor tissue gives us an opportunity to gain additional insight into immunotherapy responses in bladder cancer. The ability to evaluate tissue from both core needle biopsies and cored resection samples will support our ongoing research."
The Role of Live Tumor Fragments
Utilizing live tumor fragments represents a significant advancement in cancer research. As noted by Dr. Premal Patel, Chief Medical Officer at Elephas, there is mounting recognition of the value this approach brings to understanding drug responses in patients. The elive Edge technology will facilitate meticulous preparation and handling of these tumor samples, ensuring that they are suitable for research purposes.
Addressing the Cancer Care Dilemma
Cancer remains a leading cause of mortality globally, and projections indicate that the number of patients could triple by 2060 if current trends continue. Despite the increasing number of immunotherapy options, only a small fraction of patients derive benefits from these treatments. Many eligible patients remain unidentified due to the unavailability of accurate predictive biomarkers.
Elephas addresses this pressing issue with its ex vivo platform, which evaluates how live tumor tissue reacts to various therapies, preserving the vital tumor microenvironment. By doing so, the elive platform aims to provide crucial insights into patient care and treatment choices for those battling cancer.
Looking Towards the Future
The collaboration between Elephas Biosciences and Mount Sinai represents an important step forward in bladder cancer research. By harnessing innovative technology to analyze live tumor tissues, researchers hope to uncover critical differences in how patients respond to therapies and guide future treatments.
To explore the implications of this collaboration further and learn more about the elive technology's potential, you can visit Elephas's official website at www.elephas.com or follow their journey on LinkedIn. As hospitals and research institutions continue to partner with technology developers, the fight against cancer gets a significant boost toward personalized medicine, driven by understanding the intricacies of individual responses to treatment.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.